Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma

A 23-year experience

Brian G. Czito, Herbert I. Hurwitz, Robert W. Clough, Douglas Tyler, Michael A. Morse, Bryan M. Clary, Theodore N. Pappas, Nishan H. Fernando, Christopher G. Willett

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Purpose: Primary adenocarcinoma of the gallbladder is a rare malignancy. To better define the role of adjuvant radiation therapy and chemotherapy, a retrospective analysis of the outcome of patients undergoing surgery and adjuvant therapy was undertaken. Methods and Materials: Twenty-two patients with primary and nonmetastatic gallbladder cancer were treated with radiation therapy after surgical resection. Median radiation dose was 45 Gy. Eighteen patients received concurrent 5-fluorouracil (5-FU) chemotherapy. Median follow-up was 1.7 years in all patients and 3.9 years in survivors. Results: The 5-year actuarial overall survival, disease-free survival, metastases-free survival, and local-regional control of all 22 patients were 37%, 33%, 36%, and 59%, respectively. Median survival for all patients was 1.9 years. Conclusion: Our series suggests that an approach of radical resection followed by external-beam radiation therapy with radiosensitizing 5-FU in patients with locally advanced, nonmetastatic carcinoma of the gallbladder may improve survival. This regimen should be considered in patients with resectable gallbladder carcinoma.

Original languageEnglish (US)
Pages (from-to)1030-1034
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume62
Issue number4
DOIs
StatePublished - Jul 15 2005
Externally publishedYes

Fingerprint

chemotherapy
Gallbladder
radiation therapy
Radiotherapy
cancer
Carcinoma
Drug Therapy
Survival
Fluorouracil
Gallbladder Neoplasms
metastasis
surgery
Disease-Free Survival
Survivors
therapy
Adenocarcinoma
Radiation
Neoplasm Metastasis
dosage
radiation

Keywords

  • 5-Fluorouracil
  • Adjuvant therapy
  • Gallbladder cancer
  • Radiotherapy
  • Surgical resection

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma : A 23-year experience. / Czito, Brian G.; Hurwitz, Herbert I.; Clough, Robert W.; Tyler, Douglas; Morse, Michael A.; Clary, Bryan M.; Pappas, Theodore N.; Fernando, Nishan H.; Willett, Christopher G.

In: International Journal of Radiation Oncology Biology Physics, Vol. 62, No. 4, 15.07.2005, p. 1030-1034.

Research output: Contribution to journalArticle

Czito, Brian G. ; Hurwitz, Herbert I. ; Clough, Robert W. ; Tyler, Douglas ; Morse, Michael A. ; Clary, Bryan M. ; Pappas, Theodore N. ; Fernando, Nishan H. ; Willett, Christopher G. / Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma : A 23-year experience. In: International Journal of Radiation Oncology Biology Physics. 2005 ; Vol. 62, No. 4. pp. 1030-1034.
@article{5a17921b058146fa874b280e69afc33a,
title = "Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: A 23-year experience",
abstract = "Purpose: Primary adenocarcinoma of the gallbladder is a rare malignancy. To better define the role of adjuvant radiation therapy and chemotherapy, a retrospective analysis of the outcome of patients undergoing surgery and adjuvant therapy was undertaken. Methods and Materials: Twenty-two patients with primary and nonmetastatic gallbladder cancer were treated with radiation therapy after surgical resection. Median radiation dose was 45 Gy. Eighteen patients received concurrent 5-fluorouracil (5-FU) chemotherapy. Median follow-up was 1.7 years in all patients and 3.9 years in survivors. Results: The 5-year actuarial overall survival, disease-free survival, metastases-free survival, and local-regional control of all 22 patients were 37{\%}, 33{\%}, 36{\%}, and 59{\%}, respectively. Median survival for all patients was 1.9 years. Conclusion: Our series suggests that an approach of radical resection followed by external-beam radiation therapy with radiosensitizing 5-FU in patients with locally advanced, nonmetastatic carcinoma of the gallbladder may improve survival. This regimen should be considered in patients with resectable gallbladder carcinoma.",
keywords = "5-Fluorouracil, Adjuvant therapy, Gallbladder cancer, Radiotherapy, Surgical resection",
author = "Czito, {Brian G.} and Hurwitz, {Herbert I.} and Clough, {Robert W.} and Douglas Tyler and Morse, {Michael A.} and Clary, {Bryan M.} and Pappas, {Theodore N.} and Fernando, {Nishan H.} and Willett, {Christopher G.}",
year = "2005",
month = "7",
day = "15",
doi = "10.1016/j.ijrobp.2004.12.059",
language = "English (US)",
volume = "62",
pages = "1030--1034",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma

T2 - A 23-year experience

AU - Czito, Brian G.

AU - Hurwitz, Herbert I.

AU - Clough, Robert W.

AU - Tyler, Douglas

AU - Morse, Michael A.

AU - Clary, Bryan M.

AU - Pappas, Theodore N.

AU - Fernando, Nishan H.

AU - Willett, Christopher G.

PY - 2005/7/15

Y1 - 2005/7/15

N2 - Purpose: Primary adenocarcinoma of the gallbladder is a rare malignancy. To better define the role of adjuvant radiation therapy and chemotherapy, a retrospective analysis of the outcome of patients undergoing surgery and adjuvant therapy was undertaken. Methods and Materials: Twenty-two patients with primary and nonmetastatic gallbladder cancer were treated with radiation therapy after surgical resection. Median radiation dose was 45 Gy. Eighteen patients received concurrent 5-fluorouracil (5-FU) chemotherapy. Median follow-up was 1.7 years in all patients and 3.9 years in survivors. Results: The 5-year actuarial overall survival, disease-free survival, metastases-free survival, and local-regional control of all 22 patients were 37%, 33%, 36%, and 59%, respectively. Median survival for all patients was 1.9 years. Conclusion: Our series suggests that an approach of radical resection followed by external-beam radiation therapy with radiosensitizing 5-FU in patients with locally advanced, nonmetastatic carcinoma of the gallbladder may improve survival. This regimen should be considered in patients with resectable gallbladder carcinoma.

AB - Purpose: Primary adenocarcinoma of the gallbladder is a rare malignancy. To better define the role of adjuvant radiation therapy and chemotherapy, a retrospective analysis of the outcome of patients undergoing surgery and adjuvant therapy was undertaken. Methods and Materials: Twenty-two patients with primary and nonmetastatic gallbladder cancer were treated with radiation therapy after surgical resection. Median radiation dose was 45 Gy. Eighteen patients received concurrent 5-fluorouracil (5-FU) chemotherapy. Median follow-up was 1.7 years in all patients and 3.9 years in survivors. Results: The 5-year actuarial overall survival, disease-free survival, metastases-free survival, and local-regional control of all 22 patients were 37%, 33%, 36%, and 59%, respectively. Median survival for all patients was 1.9 years. Conclusion: Our series suggests that an approach of radical resection followed by external-beam radiation therapy with radiosensitizing 5-FU in patients with locally advanced, nonmetastatic carcinoma of the gallbladder may improve survival. This regimen should be considered in patients with resectable gallbladder carcinoma.

KW - 5-Fluorouracil

KW - Adjuvant therapy

KW - Gallbladder cancer

KW - Radiotherapy

KW - Surgical resection

UR - http://www.scopus.com/inward/record.url?scp=21244436280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244436280&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2004.12.059

DO - 10.1016/j.ijrobp.2004.12.059

M3 - Article

VL - 62

SP - 1030

EP - 1034

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -